Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration.

Abstract

PURPOSE:

To evaluate the efficacy of intravitreal ranibizumab with a "pro re nata" regimen in the treatment of nonsubfoveal neovascular membranes secondary to age-related macular degeneration.

METHODS:

Retrospective noncomparative case series. Thirty-one eyes with naive nonsubfoveal neovascularization secondary to age-related macular degeneration were consecutively enrolled and treated with ranibizumab intravitreal injections according to a pro re nata regimen. The follow-up was performed monthly up to 6 months and quarterly up to 2 years (25 patients). Early treatment diabetic retinopathy study best-corrected visual acuity and lesion size analysis with fluorescein angiography were recorded.

RESULTS:

The mean baseline early treatment diabetic retinopathy study best-corrected visual acuity worsened from 20/40 (0.28 logMAR) at baseline to 20/50 (0.42 logMAR) at 1-year follow-up and 20/60 (0.53 logMAR) at 2-year follow-up. The mean lesions size nearly doubled from baseline at the 2-year follow up (1.19-2.47 mm). Twenty-two patients had one or more recurrences at 1-year follow-up. All 25 patients developed a recurrence at 2 years with 7 cases developing a recurrence by 12 months. Twelve cases progressed to subfoveal lesions by the 24-month visit.

CONCLUSION:

Other regimens described in the literature might result in a more the satisfactory outcome using more frequent follow-up and more frequent intravitreal injections.

• Authors: Giovanni Giacomelli, Fabrizio Giansanti, Lucia Finocchio, Ilaria Biagini, Daniela Bacherini, Gianni Virgili, Ugo Menchini
• Journal: Retina (Philadelphia, Pa.) (Retina) Vol. 34 Issue 5 Pg. 860-7 (May 2014) ISSN: 1539-2864 [Electronic] United States
• PMID: 24756034 (Publication Type: Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Coloring Agents
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Indocyanine Green
• Ranibizumab

Topics

• Aged
• Aged, 80 and over
• Angiogenesis Inhibitors (administration & dosage, therapeutic use)
• Antibodies, Monoclonal, Humanized (administration & dosage, therapeutic use)
• Choroidal Neovascularization (drug therapy, physiopathology)
• Coloring Agents
• Female
• Fluorescein Angiography
• Fovea Centralis
• Humans
• Indocyanine Green
• Intravitreal Injections
• Male
• Middle Aged
• Ranibizumab
• Retrospective Studies
• Tomography, Optical Coherence
• Treatment Outcome
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity (physiology)
• Wet Macular Degeneration (diagnosis, drug therapy, physiopathology)